Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV

Wachtlin, Joachim; Stroux, Andrea; Wehner, Andreas; Heimann, Heinrich; Foerster, Michael

doi:10.1007/s00417-004-1071-z

Cited by 15 publications

(12 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several therapeutic alternatives, including thermal laser photocoagulation [3,4,5,6,7,8,9,10,11,12], photodynamic therapy (PDT) [13,14,15,16], surgical removal of CNV [17] or intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections [18,19,20,21,22,23,24,25,26,27,28], have been shown to be effective in the treatment of CNV due to AMD. Nevertheless, the majority of studies about CNV treatment concerned subfoveal or juxtafoveal CNV lesions.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Ladas¹,

Chatziralli²,

Kotsolis³

et al. 2012

Ophthalmologica

View full text Add to dashboard Cite

Background: To compare the efficacy of thermal laser photocoagulation versus intravitreal ranibizumab for the treatment of extrafoveal classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods: We conducted a retrospective study on 24 eyes with extrafoveal classic CNV secondary to AMD, treated either with thermal laser photocoagulation (group 1) or with intravitreal ranibizumab (group 2). Visual acuity, number of injections/sessions and recurrence rate were assessed. Results: The mean follow-up time was 23.6 ± 2.26 and 19.1 ± 9.74 months for group 1 and 2, respectively. Mean best corrected visual acuity (BCVA) of groups 1 and 2 was 0.59 ± 0.32 and 0.46 ± 0.30 logMAR, respectively (p = 0.343). At the end of the follow-up, mean BCVA of group 1 was 0.92 ± 0.35 and of group 2 0.16 ± 0.12 logMAR and differed statistically compared to baseline (p = 0.02 and p = 0.006, respectively). There was a statistically significant difference between the two groups as far as BCVA at the end of the follow-up was concerned (p < 0.0001). The patients in group 1 received on average 1.38 sessions of thermal laser photocoagulation, while patients in group 2 received on average 4 injections of ranibizumab. The recurrence rate in the laser group was 84.6%, while in the ranibizumab group it was 18.2% (p < 0.001). Specifically, the mean time of recurrence in the laser group was 11.5 months, whereas in the ranibizumab group it was 18 months (p = 0.048). Conclusion: Intravitreal ranibizumab showed promising results in BCVA improvement and decrease in macular thickness in patients with extrafoveal classic CNV due to AMD, with a small number of injections. Laser photocoagulation treatment presented worsening in BCVA and high recurrence rate in our study with long-term follow-up.

show abstract

Section: Introductionmentioning

confidence: 99%

Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Ladas¹,

Chatziralli²,

Kotsolis³

et al. 2012

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…In one eye vision had improved by 1 line at 6 months, and the remaining eye gained 1 line at the 12-month examination. Recently, Wachtlin and co-workers reported on juxtafoveal and extrafoveal CNV secondary to AMD treated by verteporfin PDT [12]. In 17 eyes with a follow-up time of 12 months, the mean visual acuity improved ±0.8±2.5 lines from baseline.…”

Section: Discussionmentioning

confidence: 99%

“…It does not cause a sudden scotoma, and the therapy spares neurosensory retina overlying the CNV lesion. Currently, there is limited information on verteporfin PDT for extrafoveal or juxtafoveal CNV in AMD [2,4,9,12]. In this study we report on the results of verteporfin PDT for the extrafoveal predominantly classic CNV lesions secondary to AMD.…”

Section: Introductionmentioning

confidence: 97%

Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration

Voelker

Gelişken

Ziemssen

et al. 2005

Graefe's Arch Clin Exp Ophthalmo

Self Cite

View full text Add to dashboard Cite

show abstract

“…Using criteria from the MPS, choroidal neovascularization was considered to be extrafoveal if its closest point did not extend closer than 200 µ to the center of the FAZ, and was classified as juxtafoveal if the closest point was closer than 200 µ to the center but did not extend under the center of the FAZ. The determination of whether the neovascularization was predominantly classic or occult was made using previously reported criteria (12) .…”

Section: Methodsmentioning

confidence: 99%

“…Thermal laser treatment can however potentially eradicate CNV, preventing the need for repeated injections of a VEGF inhibitor. Evidence for the use of PDT for the treatment of extrafoveal and juxtafoveal CNV associated with AMD has also been published, but is limited and has had highly variable results (12)(13)(14)(15) .…”

Section: Introductionmentioning

confidence: 99%

Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration

Roller

Amaro

2009

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

125 µ) or many intermediate size (63-124 µ) drusen were included. Best corrected Snellen visual acuity and optical coherence tomography (OCT) analysis of the central macular thickness was recorded for each visit. Serial injections of bevacizumab and/or ranibizumab were administered until there was resolution of subretinal fluid clinically or by OCT. Data over the entire follow-up period were analyzed for overall visual acuity and OCT changes. All patients had follow-up since diagnosis of at least 6 months (mean=9.6 months). RESULTS: Of the thirteen included patients, eleven had reduction of retinal thickening in the area involved by the CNV. The remaining two patients did not have OCT data available but had no fluid or activity on clinical examination at last follow-up. One patient (8%) lost one line of vision; one (8%) remained stable, and eleven (84%) gained one or more lines of visual acuity. Three patients (23%) gained three or more lines. The average treatment outcome for all patients was a gain of 1.7 ± 1.3 lines of Snellen acuity. Both therapeutic agents were effective, with an average gain of 1.6 ± 0.6 lines for patients treated with bevacizumab, 1.5 ± 1.9 lines gained for patients treated with ranibizumab and 2.5 ± 0.7 lines gained in the two patients who received both agents over the course of their treatment. CONCLUSIONS: The use of intravitreal anti-VEGF agents for nonsubfoveal CNV in AMD is effective. Our results are comparable to published results from large-scale trials of anti-VEGF therapy for subfoveal CNV. Our data support the idea that bevacizumab or ranibizumab appear to be the treatment of choice for AMD patients with nonsubfoveal CNV.]]>

show abstract

Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV

Cited by 15 publications

References 17 publications

Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Intravitreal Ranibizumab versus Thermal Laser Photocoagulation in the Treatment of Extrafoveal Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation secondary to age-related macular degeneration

Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration

Contact Info

Product

Resources

About